**Supplemental Table 1**: Reason Time Out Not Indicated

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Early Time Out in ATO-A and B** | **Late Time Out in ATO-A and B** | **Early Time Out in UC ATO-B** | **Late Time Out in UC ATO-B** |
| Died | 0 | 1 | 0 | 0 |
| Discharged | 2 | 83 | 0 | 30 |
| Antibiotic Stopped | 0 | 12 | 0 | 6 |
| ID Consulted | 26 | 35 | 26 | 27 |
| Prophylaxis already evaluated | 0 | 6 | 0 | 1 |
| Other | 0 | 2 | 0 | 2 |
| Total | 28 | 139 | 26 | 66 |

**Supplemental Table 2:** Individual Antibiotic Use Measured in DOT/1000 Medicine Days

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **ATO-A (N=135)** | **ATO-B (N=114)** | **UC-A (N=156)** | **UC ATO-B (N=133)** | *P* |
| All vancomycin | 184 | 140 | 198 | 195 | 0.18 |
| IV Vancomycin | 159 | 126 | 190 | 168 | 0.46 |
| PO vancomycin | 25 | 13 | 8 | 27 | 0.26 |
| All Linezolid | 20 | 11 | 3 | 3 | 0.62 |
| IV linezolid | 5 | 6 | 3 | 3 | 0.98 |
| PO linezolid | 15 | 6 | 0 | 0 | 0.88 (A vs. B) |
| All Levofloxacin | 174 | 124 | 132 | 99 | 0.22 |
| IV levofloxacin | 46 | 27 | 49 | 20 | 0.013 (A vs. D 0.042, C vs. D 0.022) |
| PO levofloxacin | 128 | 98 | 83 | 78 | 0.77 |
| Piperacillin/tazobactam | 155 | 132 | 126 | 153 | 0.75 |
| Cefepime | 20 | 18 | 33 | 10 | 0.30 |
| Meropenem | 5 | 6 | 17 | 58 | 0.17 |
| Ertapenem | 35 | 6 | 29 | 11 | 0.50 |
| Ceftriaxone | 119 | 97 | 100 | 93 | 0.86 |